Melissa L. Thompson Bastin, PharmD, PhD

University of Kentucky Medical Center

Disclosure(s): Baxter Healthcare: Advisor/Consultant, Board Member; Fresenius: Advisor/Consultant

Poster(s):

• (P-1217) Validation of Cefiderocol (FDC) Package Insert Dosing Recommendation for Patients receiving Continuous Renal Replacement Therapy (CRRT): A Prospective Multi-Center Pharmacokinetic Study
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT